Elmind Capital LP Buys Shares of 112,000 Amylyx Pharmaceuticals, Inc. $AMLX

Key Points

• Elmind Capital LP acquired 112,000 Amylyx Pharmaceuticals shares in the second quarter, valued at approximately $2.0 billion according to its latest SEC filing. The position represents 0.10% of Amylyx and about 0.5% of Elmind’s portfolio.
• Institutional ownership remains high at 95.84%, with several hedge funds and investment firms recently initiating or increasing positions in Amylyx.
• Analysts generally remain bullish, with a consensus “Buy” rating and an average price target of $36.25, although Amylyx recently missed quarterly EPS expectations and insiders have sold shares.

Elmind Capital LP purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 112,000 shares of the company's stock, valued at approximately $2,011,520,000. Amylyx Pharmaceuticals accounts for about 0.5% of Elmind Capital LP's holdings, making the stock its 28th biggest holding. Elmind Capital LP owned 0.10% of Amylyx Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV purchased a new position in Amylyx Pharmaceuticals in the first quarter worth about $26,000. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $25,000. State of Wyoming bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company's stock worth $47,000 after purchasing an additional 3,493 shares during the period. Finally, California State Teachers Retirement System purchased a new position in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $28,000. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Stock Down 1.8%

NASDAQ AMLX opened at $37.46 on Wednesday. The firm has a market cap of $4.17 billion, a price-to-earnings ratio of -26.20 and a beta of -0.21. The business has a 50-day moving average price of $21.28 and a 200-day moving average price of $17.03. Amylyx Pharmaceuticals, Inc. has a twelve month low of $8.48 and a twelve month high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Analysts Set New Price Targets

AMLX has been the subject of a number of research reports. Guggenheim upped their target price on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday, August 19th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. HC Wainwright boosted their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, August 18th. Robert W. Baird upped their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 19th. Finally, Mizuho upped their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $36.25.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the firm's stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.90% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Company Profile

Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source